Dengue serotype cross-reactive, anti-e protein antibodies confound specific immune memory for 1 year after infection.

ABSTRACT: Dengue virus has four serotypes and is endemic globally in tropical countries. Neither a specific treatment nor an approved vaccine is available, and correlates of protection are not established. The standard neutralization assay cannot differentiate between serotype-specific and serotype cross-reactive antibodies in patients early after infection, leading to an overestimation of the long-term serotype-specific protection of an antibody response. It is known that the cross-reactive response in patients is temporary but few studies have assessed kinetics and potential changes in serum antibody specificity over time. To better define the specificity of polyclonal antibodies during disease and after recovery, longitudinal samples from patients with primary or secondary DENV-2 infection were c

SUBMITTER: Toh YX 

PROVIDER: S-EPMC4132268 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature